Evidence map›Paper›PMID 25999212›Full record

Trial reportCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2015

Associations of Coffee Drinking with Systemic Immune and Inflammatory Markers.

Erikka Loftfield, Meredith S Shiels, Barry I Graubard, Hormuzd A Katki, Anil K Chaturvedi, Britton Trabert, Ligia A Pinto, Troy J Kemp, Fatma M Shebl, Susan T Mayne and 5 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 3 pooled it
6.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Erikka LoftfieldDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut. erikka.loftfield@nih.gov.
Meredith S ShielsDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Barry I GraubardDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Hormuzd A KatkiDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Anil K ChaturvediDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Britton TrabertDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Ligia A PintoHPV Immunology Laboratory, Leidos Biomedical Research, Inc., SAIC-Frederick/NCI-Frederick, Frederick, Maryland.
Troy J KempHPV Immunology Laboratory, Leidos Biomedical Research, Inc., SAIC-Frederick/NCI-Frederick, Frederick, Maryland.
Fatma M SheblDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut. Yale Cancer Center, New Haven, Connecticut.
Susan T MayneDepartment of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut. Yale Cancer Center, New Haven, Connecticut.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Mark P PurdueOntario Institute for Cancer Research, Toronto, Canada.
Allan HildesheimDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Rashmi SinhaDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Neal D FreedmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Yale Cancer Center · USOntario Institute for Cancer Research · CA

Funding

Yale/NCI Cooperative Training Program in Cancer EpidemiologyT32CA105666 · NCI · YALE UNIVERSITY · PI MA, XIAOMEI · 2008 to 2012
$603k
Intramural NIH HHS Z99 CA999999NCI NIH HHS T32 CA105666
6 · The paper itself

Abstract

backgroundCoffee drinking has been inversely associated with mortality as well as cancers of the endometrium, colon, skin, prostate, and liver. Improved insulin sensitivity and reduced inflammation are among the hypothesized mechanisms by which coffee drinking may affect cancer risk; however, associations between coffee drinking and systemic levels of immune and inflammatory markers have not been well characterized.

methodsWe used Luminex bead-based assays to measure serum levels of 77 immune and inflammatory markers in 1,728 older non-Hispanic Whites. Usual coffee intake was self-reported using a food frequency questionnaire. We used weighted multivariable logistic regression models to examine associations between coffee and dichotomized marker levels. We conducted statistical trend tests by modeling the median value of each coffee category and applied a 20% false discovery rate criterion to P values.

resultsTen of the 77 markers were nominally associated (P trend < 0.05) with coffee drinking. Five markers withstood correction for multiple comparisons and included aspects of the host response namely chemotaxis of monocytes/macrophages (IFNγ, CX3CL1/fractalkine, CCL4/MIP-1β), proinflammatory cytokines (sTNFRII), and regulators of cell growth (FGF-2). Heavy coffee drinkers had lower circulating levels of IFNγ [odds ratios (OR), 0.35; 95% confidence intervals (CI), 0.16-0.75], CX3CL1/fractalkine (OR, 0.25; 95% CI, 0.10-0.64), CCL4/MIP-1β (OR, 0.48; 95% CI, 0.24-0.99), FGF-2 (OR, 0.62; 95% CI, 0.28-1.38), and sTNFRII (OR, 0.34; 95% CI, 0.15-0.79) than non-coffee drinkers.

conclusionsLower circulating levels of inflammatory markers among coffee drinkers may partially mediate previously observed associations of coffee with cancer and other chronic diseases. IMPACT: Validation studies, ideally controlled feeding trials, are needed to confirm these associations.

Indexed as

CoffeeFeeding BehaviorImmunity, InnateAgedBiomarkersCross-Sectional StudiesFemaleHumansInflammationMaleMiddle AgedNeoplasmsOdds RatioPrevalenceRetrospective StudiesRisk AssessmentBiomarkersCoffee

Identifiers

PMID25999212
PMCPMC4490956
OpenAlexW1944072521

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.